Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 10, 2010, Pages 1178-1188

  Yoshimura, Satoshi ^a   Ochi, Hirofumi ^a   Isobe, Noriko ^a   Matsushita, Takuya ^a   Motomura, Kyoko ^a   Matsuoka, Takeshi ^a   Minohara, Motozumi ^a   Kira, Jun Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

age; BDNF; Brain derived neurotrophic factor; IFN?2; interferon beta; MS; multiple sclerosis; T cells

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA;

ARTICLE; BLOOD CELL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SERUM; T LYMPHOCYTE;

ADULT; AGING; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTOR, TRKB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES;

EID: 77957607357     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510375706     Document Type: Article

References (46)

1. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
2. Lewin GR and Barde YA Physiology of the neurotrophins. Annu Rev Neurosci 1996 ; 19: 289-317.
3. Gravel C., Gotz R., Lorrain A. and Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 1997 ; 3: 765-770.
4. McTigue DM, Horner PJ, Stokes BT and Gage FH Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 1998 ; 18: 5354-5365.
5. Kerschensteiner M., Gallmeier E., Behrens L., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999 ; 189: 865-870.
6. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R. and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002 ; 125: 75-85.
7. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H. and Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003 ; 53: 292-304.
8. Rosenfeld RD, Zeni L., Haniu M., et al. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995 ; 6: 465-471.
9. Radka SF, Holst PA, Fritsche M. and Altar CA Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996 ; 709: 122-301.
10. Fujimura H., Altar CA, Chen R., et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002 ; 87: 728-734.
11. Nassenstein C., Braun A., Erpenbeck VJ, et al. The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J Exp Med 2003 ; 198: 455-467.
12. Nakahashi T., Fujimura H., Altar CA, et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000 ; 470: 113-117.
13. Donovan MJ, Miranda RC, Kraemer R., et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 1995 ; 147: 309-324.
14. Leeksma CH and Cohen JA Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate. Nature 1955 ; 175: 552-553.
15. Poduslo JF and Curran GL Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996 ; 36: 280-286.
16. Pan W., Banks WA, Fasold MB, Bluth J. and Kastin AJ Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998 ; 37: 1553-1561.
17. Karege F., Schwald M. and Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002 ; 328: 261-264.
18. Lalive PH, Kantengwa S., Benkhoucha M., Juillard C. and Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 2008 ; 197: 147-151.
19. Azoulay D., Vachapova V., Shihman B., Miler A. and Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005 ; 167: 215-218.
20. Sarchielli P., Greco L., Stipa A., Floridi A. and Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002 ; 132: 180-188.
21. Caggiula M., Batocchi AP, Frisullo G., et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005 ; 62: 176-182.
22. Weinstock-Guttman B., Zivadinov R., Tamano-Blanco M., et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 2007 ; 188: 167-174.
23. Hamamcioglu K. and Reder AT Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007 ; 13: 459-470.
24. Azoulay D., Urshansky N. and Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008 ; 195: 186-193.
25. Sarchielli P., Zaffaroni M., Floridi A., et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 2007 ; 13: 313-331.
26. Blanco Y., Moral EA, Costa M., et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006 ; 406: 270-275.
27. Petereit HF, Lindemann H. and Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler 2003 ; 9: 16-20.
28. Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58: 840-846.
29. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
30. Kira J., Kanai T., Nishimura Y., et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996 ; 40: 569-574.
31. Matsuoka T., Matsushita T., Kawano Y., et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130: 1206-1223.
32. Matsushita T., Isobe N., Matsuoka T., et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009 ; 15: 834-847.
33. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF and Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66: 1485-1489.
34. Pozzilli C., Prosperini L., Sbardella E., De Giglio L., Onesti E. and Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 2005 ; 26: S174 - S178.
35. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003 ; 2: 117-127.
36. Ishizu T., Kira J., Osoegawa M., et al. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neurol Sci 2009 ; 280: 22-28.
37. Edling AE, Nanavati T., Johnson JM and Tuohy VK Human and murine lymphocyte neurotrophin expression is confined to B cells. J Neurosci Res 2004 ; 77: 709-717.
38. Yamamoto H. and Gurney ME Human platelets contain brain-derived neurotrophic factor. J Neurosci 1990 ; 10: 3469-3478.
39. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G. and Aubry JM Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002 ; 109: 143-148.
40. Shimizu E., Hashimoto K., Okamura N., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003 ; 54: 70-75. (Pubitemid 36776725)
41. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry JM and Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005 ; 57: 1068-1072.
42. Piccinni A., Marazziti D., Catena M., et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008 ; 105: 279-283.
43. Linker R., Lee D-H., Siglienti I. and Gold R. Is there a role for neurotrophins in the pathology of multiple sclerosis? J Neurol 2007 ; 254 (Suppl): 133-140.
44. Besser M. and Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999 ; 162: 6303-6306.
45. De Santi L., Cantalupo L., Tassi M., Raspadori D., Cioni C. and Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. J Neurol Sci 2009 ; 277: 65-70.
46. Schenone A., Gill JS, Zacharias DA and Windebank AJ Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. J Neuroimmunol 1996 ; 64: 141-149.